RxDoctor Payments Data

Salman Ashfaq, MD

Interventional Cardiology · Gainesville, GANPI 1912985052

Payments from drug & device makers

$21,584in general payments, 2019–2025

Across 355 payments — averaging $60.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim Pharma GmbH & Co.kg$7K
  • Boehringer Ingelheim International GmbH$7K
  • Medtronic$1K
  • Novartis$740
  • Amgen$694
  • Pfizer$523
  • plus $5K from 39 others

What the payments were for

  • Travel & lodging$79010%
  • Food & beverage$6,97089%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,584 in reported general payments places this provider in the 65th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$869,243
Medicare patients
1,090
Services billed
10,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban990$1,031,080
Repatha SureclickEvolocumab333$440,834
FarxigaDapagliflozin Propanediol407$355,174
XareltoRivaroxaban219$218,772
JardianceEmpagliflozin272$210,011
MultaqDronedarone Hcl131$156,958
EntrestoSacubitril/Valsartan163$149,250
Ranolazine ErRanolazine752$66,780
BrilintaTicagrelor75$53,211
Praluent PenAlirocumab44$52,907
VascepaIcosapent Ethyl63$29,323
NexlizetBempedoic Acid/Ezetimibe29$19,239
Metoprolol Succinate1,711$17,212
Repatha SyringeEvolocumab11$12,602
Atorvastatin Calcium1,297$10,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$523$1,031,080990 claims
AstraZenecaFarxiga, Brilinta$414$408,385482 claims
Johnson & JohnsonXarelto$390$218,772219 claims
Boehringer IngelheimJardiance$141$210,011272 claims
Sanofi-aventis U.S. LLCMultaq$195$156,958131 claims
NovartisEntresto$740$149,250163 claims
Esperion Therapeutics, Inc.Nexlizet$209$19,23929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →